骨重塑的中枢控制

Central control of bone remodeling.

作者信息

Takeda Shu

机构信息

Department of Orthopedics, 21st Century Center of Excellence (COE) Program for Frontier Research on Molecular Destruction and Reconstruction of Tooth and Bone, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.

出版信息

Biochem Biophys Res Commun. 2005 Mar 18;328(3):697-9. doi: 10.1016/j.bbrc.2004.11.071.

DOI:10.1016/j.bbrc.2004.11.071

PMID:15694403

Abstract

The hormonal control of osteoblast activity has been speculated for a long time. In search of such a central hormone, leptin was identified as an inhibitor of bone formation. Intracerebroventricular infusion of leptin resulted in a decrease of bone mass establishing that bone mass is regulated centrally. The peripheral mediator of leptin's action was identified as being the sympathetic nervous system. Mice deficient for catecholamines have high bone mass. beta-Receptor agonists decreased bone mass, and conversely, treatment by beta-blockers increased bone mass.

摘要

长期以来，人们一直在推测成骨细胞活性的激素调控机制。为了寻找这样一种核心激素，瘦素被确定为骨形成的抑制剂。脑室内注射瘦素会导致骨量减少，这表明骨量受中枢调控。瘦素作用的外周介质被确定为交感神经系统。缺乏儿茶酚胺的小鼠骨量较高。β受体激动剂会降低骨量，相反，β受体阻滞剂治疗则会增加骨量。